Key result
Bone-marrow mononuclear cell therapy shows no benefit over standard care for MACE in chronic HF.
Why the study?
There has been no clear evidence regarding the comparative effectiveness of bone-marrow mononuclear cell therapy in patients with chronic heart failure.
Does bone-marrow mononuclear cell therapy improve clinical outcomes or LVEF in patients with chronic heart failure?
Meta-Analysis (n=379)
Does bone-marrow mononuclear cell therapy improve clinical outcomes or LVEF in patients with chronic heart failure?
Relative Risk: 0.59 (95% CI 0.14–2.46)
Absolute Event Rate: 4.65% vs 9.09%
p-value: p=0.47
A meta-analysis of 7 RCTs found no significant clinical or echocardiographic benefit of bone-marrow mononuclear cell therapy in patients with chronic heart failure.
Does not support bone-marrow mononuclear cell therapy in chronic heart failure; confirms lack of clinical benefit in meta-analysis of RCTs.
BACKGROUND: Over the past decade, there has been no clear evidence regarding the comparative effectiveness of bone-marrow mononuclear cell (BMMNC) therapy in patients with chronic heart failure (HF). METHODS: We retrieved eligible randomized controlled trials (RCTs) of bone marrow mononuclear cells (BMMNCs) in patients with heart failure (HF) using a systematic approach of PRISMA guideline and focusing on studies published between 2015 and 2025. We performed a meta-analysis on clinical outcomes, including major adverse cardiovascular events (MACE), hospitalization for HF, and mortality, as well as echocardiographic indices, such as left ventricular ejection fraction (LVEF). The analysis was conducted using a random-effects model. Risk ratios (RR) or mean differences (MD) with corresponding 95% confidence intervals (CI) were pooled based on the type of outcome. RESULTS: The analysis pooled data from 379 patients from 7 RCT studies, including 189 patients experienced BM-MNC and 190 patients in control group. While the stem cell group showed a slight improvement in left ventricular ejection fraction (LVEF) [MD=-0.73, 95%Cl (-2.14,0.68), P = 0.31] at both 3 months [MD = 2.34, 95%Cl (-1.94,6.62), P = 0.28] and 1 year [MD = 1.69, 95%Cl (-2.29,5.66), P = 0.41] compared to controls, these differences did not reach statistical significance (P > 0.05). Furthermore, stem cell therapy demonstrated no significant benefits in reducing morbidity [RR = 0.99, 95%Cl (0.40, 2.49), P = 0.99], mortality [RR = 1.55, 95%Cl (0.50,4.85), P = 0.45], rehospitalization rates [RR = 1.09, 95%Cl (0.63,1.88) P = 0.75], or major adverse cardiac events (MACE) [RR = 0.59, 95%CI (0.14, 2.46), P = 0.47], as well as injection route used (P > 0.05 for all outcomes). CONCLUSION: The analysis of 7 RCTs found no statistically significant benefits of stem cell therapy on LVEF, clinical outcomes, or MACE, regardless of injection route. Current evidence does not support its routine use; further research is warranted.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) conducted a meta-analysis in Chronic heart failure (HF) (n=379). Bone-marrow mononuclear cell (BMMNC) therapy vs. Standard care without BMMNC therapy was evaluated on Major adverse cardiovascular events (MACE) (RR 0.59, 95% CI 0.14, 2.46, p=0.47). Bone-marrow mononuclear cell therapy did not significantly reduce major adverse cardiovascular events (RR 0.59), mortality, or rehospitalization compared to standard care in patients with chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: